Results 151 to 160 of about 64,876 (258)
Advanced Science, Volume 13, Issue 8, 9 February 2026.The SNARE protein YKT6 is upregulated in bladder cancer (BLCA), correlating with poor prognosis. YKT6 promotes tumor proliferation and metastasis by activating Wnt/β‐catenin signaling. It recruits Ubiquitin‐Specific Peptidase 7 (USP7) to deubiquitinate and stabilize β‐catenin, enhancing its nuclear accumulation and driving oncogenic gene expression ...
Sheng Tu +16 more
wiley +1 more source
Advanced Science, Volume 13, Issue 8, 9 February 2026.scPER presents an adversarial‐autoencoder framework that deconvolves bulk total RNA‐seq to quantify tumor‐microenvironment cell types and uncover phenotype‐linked subclusters. Across diverse benchmarks, scPER improves accuracy over existing tools.
Bingrui Li, Xiaobo Zhou, Raghu Kalluri
wiley +1 more source
BJUI Compass, Volume 7, Issue 2, February 2026.Abstract Objective To identify factors associated with decreased adherence to the national risk‐stratified surveillance cystoscopy schedule for non‐muscle invasive bladder cancer (NMIBC). Patients and methods A retrospective, IRB‐approved review was conducted at a single academic institution to identify patients diagnosed with NMIBC who underwent ...
Katherina Y. Chen +6 more
wiley +1 more source
Streamlining urology cancer multidisciplinary team meetings: Implementation and outcomes
BJUI Compass, Volume 7, Issue 2, February 2026.Abstract Objectives This work aimed to evaluate the implementation and impact of a pre‐multidisciplinary team (MDT) triage model using Standards of Care (SoC) for streamlining in a urology cancer service. Materials and Methods An SoC framework was developed by the cancer lead in line with national guidance.
Hossein Arang +6 more
wiley +1 more source
BJUI Compass, Volume 7, Issue 2, February 2026.Abstract Objectives To evaluate the treatment outcomes of 5‐aminolevulinic acid hydrochloride (5‐ALA) photodynamic diagnosis (PDD)‐assisted transurethral resection of bladder tumour (TURBT) (ALA PDD‐TURBT, hereinafter referred to as ‘ALA‐PDD’) exceeding 4 h after ALA administration for non–muscle‐invasive bladder cancer (NMIBC).
Hideo Fukuhara +6 more
wiley +1 more source